Blood test for tumor DNA in patients with pancreatic cancer
Official title: Application of ctDNA Assay in the Neoadjuvant and Adjuvant Chemotherapy Setting in Patients With Resectable Pancreatic Cancer
Run by University of Oklahoma · NCT05052671 · Data updated 2026-11-12
This study is testing if a blood test for tumor DNA can help doctors understand how well treatment is working for people with pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Oklahoma Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Oklahoma City, Oklahoma and 1 other locations) |
| Status | Recruiting |
| Started | May 25, 2022 |
| Main results expected | December 2026 |
| Study ends | December 2028 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT05052671 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with newly diagnosed resectable or borderline resectable exocrine pancreatic cancer.
✕Probably not a fit
Patients with neuroendocrine pancreatic tumors or those with locally advanced or metastatic disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the presence of circulating tumor DNA (ctDNA) in the blood of patients with resectable or borderline resectable pancreatic cancer. Participants will undergo standard treatment, including chemotherapy and surgery, while their blood will be collected at various time points to assess ctDNA levels. The study seeks to determine the proportion of patients with positive ctDNA and its correlation with progression-free survival. By analyzing ctDNA, the research hopes to identify potential biomarkers that could enhance patient care and treatment strategies.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for patients with pancreatic cancer.
How similar studies have gone: While the use of ctDNA as a biomarker is gaining traction, this specific approach in pancreatic cancer is still being explored and may provide novel insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria 1. Newly diagnosed exocrine pancreatic cancer with either pathology or radiology imaging suggestive of adenocarcinoma 2. Resectable/Borderline Resectable Pancreatic cancer as defined by the NCCN guidelines 3. ≥ 18 years old at the time of informed consent 4. ECOG Performance Status 0 or 1 5. Patients who are candidates for neoadjuvant chemo/chemoradiotherapy or upfront surgery are eligible for the study. 6. Ability to provide written informed consent and HIPAA authorization 7. Patients must have a life expectancy of at least 6 months Exclusion Criteria 1. Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies 2. Positive pregnancy test, pregnant, or breastfeeding 3. Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study 4. Locally advanced or metastatic disease
Where it's running
-
University of Oklahoma
Oklahoma City, Oklahoma, United States Recruiting -
Stephenson Cancer Center- Tulsa
Tulsa, Oklahoma, United States Recruiting
Study contacts
- Principal investigator: Sagila George — University of Oklahoma
- Study coordinator: Lead Nurse
- Email: SCC-IIT-office@ouhsc.edu
- Phone: 1-405-271-8777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
INSPIRE: Putting patient-reported info into multidisciplinary tumor boards
This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.
-
MRI scan for detecting pancreatic cancer in people at high risk
This study tests a dedicated pancreas MRI (MRP) tool to see if it helps find pancreatic cancer earlier in people with a strong family or genetic risk.
-
Cutting down ultra-processed foods for people at high cancer risk
This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.
-
Carbon nanoparticle‑loaded iron for advanced solid tumors
This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.